Champions Oncology (CSBR) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
LeonaBio (LONA) has outperformed Champions Oncology (CSBR) over the past year, gaining 46.7% versus a loss of 26.2%. Over five years, CSBR leads with a -52.0% price change compared with -94.0% for LONA. Champions Oncology is the larger company by market cap ($67.4 million vs $54.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | LONA |
|---|---|---|
| Share price | $4.84 | $5.75 |
| Market cap | $67.37M | $54.17M |
| 1-day change | -2.81% | 0.00% |
| YTD return | -29.96% | -24.04% |
| 1-year return | -26.22% | +46.68% |
| 5-year return | -51.98% | -93.99% |
| Forward P/E | 48.40 | — |
| EPS (TTM) | $-0.07 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $14.21 |
| 52-week low | $4.59 | $2.21 |
| Distance from 52-week high | -41.76% | -59.54% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +201.39% |
| Average volume | 11.47K | 185.45K |
| Shares outstanding | 13.92M | 9.42M |
| Employees | 214 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed CSBR by 72.9 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
CSBR vs LONA FAQ
Which is bigger, Champions Oncology or LeonaBio?
Champions Oncology (CSBR) is larger, with a market capitalization of $67.37M compared with $54.17M for LeonaBio (LONA).
Which stock has performed better over the past year, CSBR or LONA?
LONA returned +46.68% over the past 12 months, compared with -26.22% for CSBR (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.